Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer

Clin Cancer Res. 2002 Dec;8(12):3857-62.

Abstract

Purpose and experimental design: The purpose is to define intratumoral microvessel density (MVD) and potential biological markers that correlate with inflammatory breast cancer (IBC), we examined MVD, estrogen receptor a (ER) status, MIB-1 proliferation index, p53, and c-erbB-2 by immunohistochemistry in archival specimens from 67 women diagnosed with breast cancer with or without the inflammatory phenotype at the Institut Salah Azaiz (Tunis, Tunisia).

Results: The moderate (25-50/x400 field) to high microvessel count (>50/x400 field) was observed in 23 (51%) of 45 IBC tumors compared with 3 (14%) of 22 non-IBC tumors (P = 0.0031; chi(2) test). The presence of ER was found in 6 (14%) of 44 cases versus 7 (32%) of 22 cases in IBC and non-IBC, respectively (P = 0.10). In this series of 67 patient tumors, the median MVD count in ER-negative breast tumors was 21, whereas the median count was 4 in ER-positive breast tumors (P = 0.08; Wilcoxon rank-sum test). However, MIB-1, p53, and c-erbB-2 were not significantly different between IBC and non-IBC tumors. The intratumoral MVD between IBC and non-IBC was still statistically significant after adjustment for multiple comparisons (P = 0.02; Bonferroni test).

Conclusions: These data suggest that there is an increased MVD in breast cancer with the inflammatory phenotype as compared with breast cancer without the inflammatory phenotype.

MeSH terms

  • Adenocarcinoma / blood supply*
  • Adenocarcinoma / metabolism
  • Adenocarcinoma / pathology
  • Adolescent
  • Adult
  • Aged
  • Biomarkers, Tumor / metabolism*
  • Breast Neoplasms / blood supply*
  • Breast Neoplasms / metabolism
  • Breast Neoplasms / pathology
  • Estrogen Receptor alpha
  • Female
  • Humans
  • Immunoenzyme Techniques
  • Ki-67 Antigen / metabolism
  • Lymphatic System / pathology
  • Middle Aged
  • Neoplasm Proteins / metabolism*
  • Neoplasm Staging
  • Neovascularization, Pathologic / pathology*
  • Prognosis
  • Receptor, ErbB-2 / metabolism
  • Receptors, Estrogen / metabolism
  • Tumor Suppressor Protein p53 / metabolism

Substances

  • Biomarkers, Tumor
  • Estrogen Receptor alpha
  • Ki-67 Antigen
  • Neoplasm Proteins
  • Receptors, Estrogen
  • Tumor Suppressor Protein p53
  • Receptor, ErbB-2